Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

Sponsor
First Affiliated Hospital of Zhejiang University
Study ID
NCT05451290
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Advanced Biliary Tract Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a phase II open-label, one-arm, multicenter study aimed to explore the efficacy and safety of perioperative (neoadjuvant and adjuvant) treatment for patients with advanced biliary tract carcinoma.

Key Dates

Start date
Nov 1, 2022
Status verified
Feb 2026
Primary completion
Dec 31, 2024
Completion
Dec 3, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment arm

Primary Outcome Measure

1-year EFS rate [ Time Frame: 1 year ]

Related Studies